{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+2&page=60",
    "query": {
      "intervention": "Experimental 2",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 4118,
    "total_pages": 412,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+2&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+2&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T11:27:27.262Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01775995",
      "title": "Meditation-CBT for Opioid-treated Chronic Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pain",
        "Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Meditation-CBT Intervention + Usual Care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care Alone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2013-01",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01775995"
    },
    {
      "nct_id": "NCT02833753",
      "title": "Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Appendix Cancer",
        "Peritoneal Carcinomatosis"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 14,
      "start_date": "2016-07",
      "completion_date": "2022-02",
      "has_results": false,
      "last_update_posted_date": "2022-05-31",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833753"
    },
    {
      "nct_id": "NCT01650545",
      "title": "Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Disorder Related to Lung Transplantation",
        "Bronchiolitis Obliterans",
        "Decreased Immunologic Activity",
        "Chronic Rejection of Lung Transplant"
      ],
      "interventions": [
        {
          "name": "Liposomal aerosol cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "standard immune suppression, oral",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2012-07",
      "completion_date": "2019-11",
      "has_results": true,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01650545"
    },
    {
      "nct_id": "NCT05413512",
      "title": "Stressor-evoked Brain and Cardiovascular Responses to Acute Psychological Stress",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Psychological Stress"
      ],
      "interventions": [
        {
          "name": "Acute psychological stress",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Baylor University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 170,
      "start_date": "2020-03-02",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Waco, Texas",
      "locations": [
        {
          "city": "Waco",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05413512"
    },
    {
      "nct_id": "NCT04003402",
      "title": "A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ASP8062",
          "type": "DRUG"
        },
        {
          "name": "Alcohol",
          "type": "DRUG"
        },
        {
          "name": "ASP8062 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Alcohol Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-07-16",
      "completion_date": "2019-10-16",
      "has_results": false,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003402"
    },
    {
      "nct_id": "NCT05780437",
      "title": "AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AZD7442",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1455,
      "start_date": "2021-02-10",
      "completion_date": "2023-06-09",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 88,
      "location_summary": "Tucson, Arizona • Chula Vista, California • Fresno, California + 59 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05780437"
    },
    {
      "nct_id": "NCT01243580",
      "title": "AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ortho-Cyclen",
          "type": "DRUG"
        },
        {
          "name": "AG200-15",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agile Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2009-08",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01243580"
    },
    {
      "nct_id": "NCT01622790",
      "title": "Evaluation of the Bioequivalence of a Combined Formulated Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir 50 mg",
          "type": "DRUG"
        },
        {
          "name": "abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 66,
      "start_date": "2012-06",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-10-15",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01622790"
    },
    {
      "nct_id": "NCT05104866",
      "title": "A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 732,
      "start_date": "2021-10-18",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05104866"
    },
    {
      "nct_id": "NCT00360737",
      "title": "Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2006-07",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-11-13T11:27:27.262Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360737"
    }
  ]
}